Table 3.
Pre- and post-therapy health-related quality of life scores as measured with National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy-Prostate Symptom Index-17 questionnaire
| Scale (maximum score) | Pre-therapy scorea | Post-therapy scorea | Change in score from baselinea | Pb |
|---|---|---|---|---|
| DRS-P (40) | 16 (9-26) | 22 (19-32) | 6 (5-15) | 0.004 |
| Lack of energy (4) | 1 (0-2) | 2 (1-3) | 0.130 | |
| Pain (4) | 1 (0-2) | 3 (3-4) | 0.003 | |
| Difficulty urinating (4) | 2 (1-4) | 3 (2-4) | 0.020 | |
| Loss of weight (4) | 3 (1-4) | 2 (1-4) | 0.773 | |
| Bone pain (4) | 1 (0-2) | 3 (3-4) | 0.007 | |
| Fatigue (4) | 2 (0-2) | 2 (2-3) | 0.016 | |
| Weakness in legs (4) | 1 (0-2) | 2 (1-3) | 0.079 | |
| Restriction in activity (4) | 1 (1-3) | 3.5 (1.8-4) | 0.016 | |
| Appetite (4) | 2 (1-4) | 2 (1-3) | 0.713 | |
| Sleep (4) | 3 (2-3) | 3 (2-3) | 1.000 | |
| DRS-E (4) | 1 (1-3) | 3 (2-3) | 1 (0-1) | 0.046 |
| TSE (16) | 8 (6.7-13.3) | 10.7 (7-13.3) | 0 (−1.4-2.7) | 0.672 |
| F/WB (8) | 4 (3-5) | 5 (3-8) | 0 (−1-3) | 0.136 |
| Total FPSI-17 (68) | 29.8 (20.2-44.6) | 41.3 (32.9-57.4) | 10.6 (2.1-23.3) | 0.003 |
aVariables expressed as median and interquartile range (1st quartile – 3rd quartile), bComparison of pre- and post-therapy scores: P value calculated using Wilcoxon Signed Rank test. DRS-E: Disease-related symptoms – emotional, DRS-P: Disease-related symptoms – physical, FPSI: FACT Prostate Symptom Index, F/WB: Function/well-being, TSE: Treatment side-effects